 Wysłany: Nie 13:17, 24 Kwi 2011 Temat postu: C-erbB-2, P53, ER, PR expression in breast cancer |
|
| C-erbB-2, P53, ER,tory burch outlet, PR expression in breast cancer and clinical significance
【Abstract】 Objective C-erbB-2, P53, and estrogen receptor and progesterone receptor expression in breast cancer and clinical pathological relationships. Methods 98 cases of breast cancer specimens of paraffin section immunohistochemistry SP method. Results 98 cases of breast cancer C-erbB-2, P53, ER, PR positive expression rate was 81.6%, 79.6%, 63.3%, 59.2%, C-erbB-2, P53 expression and prognosis of breast cancer positive correlation, ER, PR expression and metastasis and prognosis of breast cancer was negative. Conclusion C-erbB-2, P53 positive expression is an indicator of breast cancer patients with poor prognosis, ER, PR expression in breast cancer patients suggest a good prognosis, the joint detection of C-erbB-2, P53, ER, PR help breast cancer Treatment and prognosis of patients. Key words breast cancer; C-erbB-2; P53; estrogen receptor; progesterone receptor; immunohistochemistry 【Abstract】 Objective To study the clinical significance of expression of C-erbB-2, P53, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer.Methods The expression of C-erbB-2, P53, ER and PR were examined by using SP immunohistochemical staining technique on paraffin-embedded specimens of 98 cases of breast cancer without chemotherapy. Results The positive rate of C-erbB-2, P53, ER and PR were 81.6%, 79.6%, 63.3% and 59.2%, respectively. The expression of C- erbB-2 and P53 was positively related to the metastasis and prognosis of breast cancer, with the expression of ER and PR being negatively.Conclusion ombined detection of C-erbB-2, P53, ER and PR expression is valuable to estimation of prognosis and treatment of breast cancer. 】 【Key words breast cancer; C-erbB-2; P53; ER; PR; immunohistochemistry Breast cancer is the most common malignancy of women in Western countries the incidence rate of malignant tumors of the female first, and there is increasing its incidence trends. Breast cancer, development and a variety of genes and closely related to the molecular level, this group of researchers detected by immunohistochemistry C-erbB-2 (proto-oncogene), P53 (mutation), ER (estrogen receptor ), PR (progesterone receptor) in breast cancer, and thus the effectiveness and accuracy of the statistics of breast cancer prognosis and its clinical significance. 1 Materials and methods 1.1 Materials Materials for the 2005-2007 hospital surgical specimens of 98 patients with breast cancer, preoperative radiotherapy and chemotherapy without making, a clear pathological diagnosis, both female patients, all the invasive ductal carcinoma, aged 27 to 73 years, average 50 years of age, clinical TNM staging of breast cancer according to WHO criteria (2003), Ⅰ, 41 cases, Ⅱ of the 35 cases, Ⅲ of 22 cases, tumor diameter of 1 ~ 10cm, 55 patients with axillary lymph node metastasis, 43 cases without lymph node metastasis. 1.2 Methods 1.2.1 staining reagent C-erbB-2, P53, ER, PR monoclonal antibody and SP were immunohistochemical kit were purchased from Shanghai Long Jia company. 1.2.2 Immunohistochemical xylene dewaxing, graded ethanol dehydration, 3% hydrogen peroxide inactivation of endogenous peroxidase, PBS buffer to wash, microwave oven for antigen retrieval, normal goat serum closed, a Anti-4 ℃ overnight, secondary antibody, three against the 1h, DAB color 7 ~ 10min, stained nuclear dehydration transparent, neutral gum were mounted, observed under microscope. 1.3 criteria P53, ER, PR brown particles appeared in the nucleus is positive, C-erbB-2 to membrane or cytoplasmic brown granules appear as positive standard, no coloring and negative,> 10% positive. 1.4 χ2 test statistical method. 2 results 2.1 breast cancer and C-erbB-2, P53, ER, PR expression in Table 1, in 98 cases of breast cancer C-erbB-2, P53 , ER, PR positive expression rate was 81.6%, 79.6%, 63.3%, 59.2%, C-erbB-2 and P53 expression and clinical stage, axillary lymph node metastasis was significantly different (P 0.05). 2.2 C-erbB-2 and P53 protein expression in Table 2, the difference was not significant (P> 0.05). Table 1 breast cancer and C-erbB-2, P53, ER, PR protein expression in Table 2 CerbB-2 and P53 protein expression Note: The χ2 test P> 0.05 |
|
